Analyst Reco. 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
26.38 ^USD	0.00%		+13.46%	+30.21%

15/04	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
15/04	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	15/04	MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	15/04	MT
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing	04/04	MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating	01/04	MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating	01/04	MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating	05/02	MT
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell	05/02	MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk	05/02	MT
Chardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy Rating	11/23/11	MT
Chardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price Target	05/23/05	MT
BofA Adjusts Price Target on 4D Molecular Therapeutics to $33 From $28, Keeps Buy Rating	08/23/08	MT
SVB Securities Trims Price Target on 4D Molecular Therapeutics to $13 From $14, Keeps Market Perform Rating	13/23/13	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $14 From $15, Maintains Market Perform Rating	06/23/06	MT
BMO Capital Starts 4D Molecular Therapeutics at Outperform With $50 Price Target	30/23/30	MT
HC Wainwright Starts 4D Molecular Therapeutics at Buy With $36 Price Target	18/22/18	MT
Goldman Sachs Upgrades 4D Molecular Therapeutics to Buy From Neutral, Raises Price Target to $68 From $12	15/22/15	MT
SVB Securities Raises 4D Molecular Therapeutics' Price Target to $15 From $11, Keeps Market Perform Rating	14/22/14	MT
Evercore ISI Adjusts 4D Molecular Therapeutics Price Target to $45 From $32, Maintains Outperform Rating	14/22/14	MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $11 From $10, Maintains Market Perform Rating	10/22/10	MT
SVB Securities Downgrades 4D Molecular Therapeutics to Market Perform From Outperform Rating, Adjusts Price Target to $12 From $28	12/22/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Analyst Reco.

Filters